Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is a leading cause of kidney failure, marked by chronic inflammation and fibrosis.
• The complement system, particularly anaphylatoxins C3a and C5a, is increasingly recognized for its role in DKD pathogenesis.
• Anaphylatoxins mediate critical processes including inflammation, oxidative stress, and fibrosis in the kidney.

Purpose of the Study:

• To review the involvement of complement anaphylatoxins in the pathogenesis of diabetic kidney disease.
• To highlight the roles of C3a and C5a in DKD-related glomerulopathy, tubulointerstitial damage, and immune cell infiltration.
• To discuss the potential of novel anti-diabetic drugs targeting the complement system.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the role of complement anaphylatoxins in DKD.
• Evaluation of complement blockade and targeted therapeutics.

Main Results:

• Anaphylatoxins C3a and C5a are key mediators in DKD development and progression.
• These molecules contribute to glomerulopathy, tubulointerstitial damage, and inflammation in DKD.
• Complement blockade has shown promise in preclinical DKD models.

Conclusions:

• Anaphylatoxins are significant contributors to DKD pathophysiology.
• Targeting anaphylatoxins represents a potential therapeutic avenue for DKD.
• Future therapies may focus on complement system modulation for DKD treatment.